Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Anges, Inc.
NASS 2020: Neurosurgeons Discuss New Technologies For Spine Surgery – Robotics, Navigation, 3D Printing, AR
In a panel discussion, neurosurgeons forecast a bright future for robotics spine surgery and a wish list for technological improvements.
As the clock ticks down to the US election day on 3 November, President Trump maintains that the first COVID-19 vaccine emergency use approval is imminent. Meanwhile, Fujifilm Toyama's Avigan is near to Japanese approval.
The average return for companies that went public in the US through the end of September was 49.4% as of 5 October. The fourth quarter started with four additional initial public offerings on 1 October.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- AnGes Co., Ltd.
- AnGes MG